Genetic Variability and Biomarkers in Children With Acute Lung Injury (BALI)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Children's Hospital & Research Center Oakland
University of California, San Francisco
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT01048996
First received: January 13, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted

January 13, 2010
January 13, 2010
October 2009
November 2011   (final data collection date for primary outcome measure)
Development of ALI or ARDS [ Time Frame: During PICU stay ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Genetic Variability and Biomarkers in Children With Acute Lung Injury
Genetic Variability and Biomarkers in Children With Acute Lung Injury

Acute Lung Injury (ALI) and the more severe Acute Respiratory Distress Syndrome (ARDS) are a significant problem in Pediatric Intensive Care Units, affecting up to 16 of every 1000 children admitted to these units. These disorders carry with them high mortality rates as well as numerous long-term effects for the surviving children. As the effects of these diseases have significant social and economic ramifications for affected children and their families, research on the development of ALI/ARDS could significantly change how physicians understand the disease and treat patients.

There are a wide range of problems which make certain PICU patients more likely to develop either ALI or ARDS. This research aims to determine which of these children are at the greatest risk for ALI/ARDS by examining differences in plasma biomarkers and in DNA of a large number of PICU patients. We are hypothesizing that significant differences in the level of specific plasma biomarkers or in the frequency of specific DNA variants exist in children who develop ALI/ARDS.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

3 samples will be collected from each patient, one whole blood and three plasma samples will be retained.

Non-Probability Sample

Subjects will be recruited concurrently with subjects recruited for the "RESTORE" sedation study. All patients who have been admited to a Pediatric Intensive/Critical Care Unit and on mechanical ventilation will be screened for eligibility at the participating institutions.

  • Acute Respiratory Distress Syndrome
  • Acute Lung Injury
Not Provided
  • Non ALI/ARDS
    Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
  • ALI/ARDS
    Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
2450
November 2011
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Consecutive intubated pediatric patients (≥ 2 weeks of age and ≥ 42 weeks corrected gestational age and ≤ 18 years of age) supported on mechanical ventilation for acute pulmonary parenchymal disease enrolled in the RESTORE study.

Exclusion Criteria:

  • Intubated and mechanically ventilated for immediate post-operative care and stabilization
  • Cyanotic heart disease with unrepaired or palliated right to left intracardiac shunt
  • History of single ventricle at any stage of repair
  • Congenital diaphragmatic hernia or paralysis
  • Primary pulmonary hypertension
  • Critical airway (e.g., post laryngotracheal construction) or anatomical obstruction of the lower airway (e.g., mediastinal mass)
  • Ventilator dependent (including noninvasive) on PICU admission (chronic assisted ventilation)
  • Neuromuscular respiratory failure
  • Spinal cord injury above the lumbar region
  • Pain managed by patient controlled analgesia (PCA) or epidural catheter
  • Family/medical team has decided not to provide full support (patient treatment considered futile)
  • Enrolled in any other sedation clinical trial concurrently or within the last 30 days
  • Known allergy to any of the study medications
Both
up to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01048996
663, 1R01HL095410-01A1
No
Michael Quasney, MD, Medical College of Wisconsin
National Heart, Lung, and Blood Institute (NHLBI)
  • Children's Hospital & Research Center Oakland
  • University of California, San Francisco
Principal Investigator: Michael Quasney, PhD, MD Medical College of Wisconsin
National Heart, Lung, and Blood Institute (NHLBI)
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP